Rezolute (NASDAQ:RZLT) Stock Price Target Raised at Wedbush

Rezolute logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wedbush raised its price target on Rezolute from $6 to $10 and maintained an “outperform” rating, implying 179.33% upside from the stock’s current price.
  • Analyst views are mostly positive but mixed: 12 analysts rate the stock Buy and two rate it Sell; the consensus rating is “Moderate Buy,” with an average price target of $11.67.
  • Rezolute shares opened at $3.58 and were down 1.9%. The company reported a quarterly loss of $0.18 per share, slightly better than analysts’ $0.19 loss estimate.
  • Interested in Rezolute? Here are five stocks we like better.

Rezolute (NASDAQ:RZLT - Get Free Report) had its price target boosted by equities research analysts at Wedbush from $6.00 to $10.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Wedbush's target price would indicate a potential upside of 179.33% from the company's current price.

Several other equities analysts have also recently issued reports on RZLT. Citizens Jmp upped their price objective on Rezolute from $11.00 to $15.00 and gave the company a "market outperform" rating in a research report on Tuesday, October 6th. HSBC upgraded Rezolute to a "buy" rating in a research note on Friday, September 25th. Zacks Research lowered Rezolute from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 13th. Lake Street Capital boosted their price target on Rezolute from $9.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday, October 6th. Finally, Citigroup restated a "market outperform" rating on shares of Rezolute in a research note on Thursday, October 15th. Twelve investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $11.67.

Read Our Latest Stock Report on RZLT

Rezolute Stock Down 1.9%

Shares of Rezolute stock opened at $3.58 on Tuesday. Rezolute has a 52-week low of $1.07 and a 52-week high of $11.16. The company has a 50-day simple moving average of $4.05 and a two-hundred day simple moving average of $3.93.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. As a group, analysts anticipate that Rezolute will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of Rezolute

A number of large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its stake in Rezolute by 273.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company's stock valued at $1,617,000 after buying an additional 388,346 shares during the last quarter. Siren L.L.C. bought a new position in shares of Rezolute during the 1st quarter valued at $10,151,000. Jennison Associates LLC purchased a new position in shares of Rezolute in the 1st quarter worth $10,489,000. Bank of New York Mellon Corp purchased a new position in shares of Rezolute in the 2nd quarter worth $1,104,000. Finally, Wellington Management Group LLP bought a new stake in shares of Rezolute in the second quarter worth $276,000. 82.97% of the stock is currently owned by institutional investors.

Rezolute Company Profile

(Get Free Report)

Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company's lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia.

Further Reading

Analyst Recommendations for Rezolute (NASDAQ:RZLT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Rezolute Right Now?

Before you consider Rezolute, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rezolute wasn't on the list.

While Rezolute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines